Scientific Poster Session III - Original Research

Abstract

Research Question or Hypothesis: The purpose of this study is to evaluate the short-term safety and efficacy of converting from parenteral Remodulin to generic treprostinil during hospitalization.

Study Design: This IRB-approved retrospective, quasi-experimental study included adult patients on parenteral Remodulin at home admitted to a quaternary medical center between 1/1/17-2/28/23. The pre-group continued brand Remodulin, while the post-group switched to generic treprostinil.

Methods: The primary outcome was clinical deterioration up to 72 hours after initiating a hospital supplied medication. Clinical deterioration was defined as one or more of the following: 10% decrease in mean arterial pressure, 20% increase in heart rate, or escalation of respiratory support from initiation of hospital supplied medication. Secondary outcomes included rate of prostacyclin-related adverse effects and cost. Descriptive data was analyzed using measures of central tendency. Continuous data was assessed with Mann-Whitney U test, and nominal and categorical with Chi-square or Fisher’s Exact test. Statistical analysis completed with SPSS software.

Results: 104 patients were included in the study. Clinical deterioration occurred in 43 of 70 patients (61.4%) in the pre-group and 15 of 34 patients (44.1%) in the post-group (p-value=0.095). Adverse event occurred in 57 (81%) vs 30 (88.2%) patients (p-value=0.379). Average cost per patient was $2,924.66 vs $1,013.62 (p-value=0.001).

Conclusion: Converting hospitalized patients to generic treprostinil is safe and effective while resulting in decreased inpatient costs. Rates of adverse effects were similar.

Presenting Author

Authors